Avid Bioservices Announces Appointment of Magnus Schroeder, Ph.D., as Vice President of Process Sciences
08 Mai 2018 - 2:05PM
-- Addition of Senior Executive with Significant
Process Science Experience Supports Company’s Efforts to Expand and
Enhance Process Development Capabilities --
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated
contract development and manufacturing organization (CDMO) working
to improve patient lives by providing high quality development and
manufacturing services to biotechnology and pharmaceutical
companies, today announced the appointment of Magnus Schroeder,
Ph.D., as vice president of process sciences. Dr. Schroeder is an
accomplished scientist with more than 16 years of experience
spanning bioprocess development, cGMP manufacturing, CMC strategy
and global project leadership. In his new role, he will be
responsible for overseeing Avid’s process sciences function,
including the development of compliant, robust and scalable
processes, implementation of state-of-the-art, high-throughput
process development technologies, and efficient “on-boarding” of
new client programs. As part of these efforts, Dr. Schroeder
will directly manage the company’s technology collaborations, as
well as its completion of development of its novel CHO-based
mammalian expression system.
Dr. Schroeder most recently served as a director
at AGC Biologics, formerly CMC Biologics, a global contract
development and manufacturing organization, where he participated
in the successful commercial launch of multiple products. In
that role, he successfully supported more than 25 client projects
as they progressed toward first-in-human clinical trials,
commercial product launch and ongoing commercial supply.
These efforts included creative resolution of complex challenges
related to commercial processes that directly impacted a range of
regulatory interactions and filings. In directing AGC’s
purification development team, Dr. Schroeder oversaw early-to-late
phase development, process characterization, process control
strategy, commercial process support and technology
transfer/facility fit activities. Prior to AGC Biologics, Dr.
Schroeder held multiple senior level positions with CSL Limited, a
global leader in the field of biotechnology. During his
tenure, he served as senior manager and senior scientist, leading
process development activities for a range of CSL’s innovative
biologics. He has also held key process science positions
with Dynavax Technologies, in which he was responsible for
supporting process development, characterization and validation for
multiple programs. Dr. Schroeder earned his Ph.D. in
biochemical engineering and his master of science in molecular
biotechnology from Bielefeld University in Bielefeld,
Germany. He has previously served as a visiting scientist for
protein purification at Rensselaer Polytechnic Institute and a
visiting scientist for cell culture engineering at the University
of Minnesota.
“As we continue to strategically increase our
focus on process development to best align with industry needs, we
have prioritized supplementing our in-house process science
talent. With Magnus joining our team as vice president of
process sciences, we have significantly strengthened the company’s
expertise in this critical area, positioning us to continue to
deliver our customers industry-leading service and results,” said
Roger Lias, Ph.D., Avid’s president and chief executive officer.
“Importantly, we believe that the innovative process development
insights and approaches that Magnus is bringing to Avid will
further support our new customer acquisition efforts by
highlighting additional unique competitive advantages that we can
offer companies with biopharmaceutical development and
manufacturing needs.”
About Avid Bioservices,
Inc.Avid Bioservices is a dedicated contract development
and manufacturing organization (CDMO) focused on development and
cGMP manufacturing of biopharmaceutical products derived from
mammalian cell culture. The company provides a comprehensive
range of process development, high quality cGMP clinical and
commercial manufacturing services for the biotechnology and
biopharmaceutical industries. With 25 years of experience
producing monoclonal antibodies and recombinant proteins in batch,
fed-batch and perfusion modes, Avid's services include cGMP
clinical and commercial product manufacturing, purification, bulk
packaging, stability testing and regulatory strategy, submission
and support. The company also provides a variety of process
development activities, including cell line development and
optimization, cell culture and feed optimization, analytical
methods development and product characterization.
www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Okt 2023 bis Okt 2024